Biochemical Responses to Bezafibrate Improve Long-term Outcome in Asymptomatic Patients with Primary Biliary Cirrhosis Refractory to UDCA

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2014 Sep 21

PMID 25239675

Citations 14

Authors

Atsushi Tanaka

Junko Hirohara

Yasuni Nakanuma

Hirohito Tsubouchi

Hajime Takikawa

Affiliations

Soon will be listed here.

Abstract

Background: Bezafibrate is reported to have biochemical efficacy for patients with primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA), yet the long-term effect is still unknown. In Japan, nationwide surveys of PBC have been performed since 1980. In the current study, we retrospectively examined whether response to bezafibrate treatment is associated with the long-term outcomes using this large-scale database.

Methods: Among 7,376 patients in the database, we enrolled patients who were treated with UDCA at 13-15 mg/kg per day and followed up for at least 2 years after diagnosis. Bezafibrate (400 mg/day) was administered in addition to UDCA when biochemical response to UDCA was not optimal. Response to bezafibrate treatment was determined by serum alanine transaminase (ALT) levels within 2-3 years or at the earliest point thereafter from the commencement of bezafibrate treatment.

Results: We enrolled 1,121 PBC patients, and the observational period was 6.1 ± 3.4 years. Among the PBC patients, 835 were asymptomatic, defined as no liver-related symptoms at the baseline. In asymptomatic PBC patients, multivariate analysis indicated that ALT response to bezafibrate treatment was significantly associated with the presence of liver-related symptoms at the end of observation [hazard ratio 1.46 (95 % confidence interval 1.01-2.13), P = 0.048]. The cumulative liver-related-symptoms-free rate of patients treated with bezafibrate and who had a normal ALT level was significantly higher than that of those treated with bezafibrate and who had an elevated ALT level (P < 0.001), and was comparable to that of those who received UDCA monotherapy.

Conclusion: These results suggested that normalization of ALT levels with additional bezafibrate treatment significantly decreased the rate of occurrence of liver-related symptoms in asymptomatic PBC patients with suboptimal response to UDCA.

Citing Articles

Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis.

Zhu H, Zheng M, He H, Lei H, Tai W, Yang J Sci Rep. 2024; 14(1):31369.

PMID: 39732944 PMC: 11682153. DOI: 10.1038/s41598-024-82854-1.

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.

Kasztelan-Szczerbinska B, Rycyk-Bojarzynska A, Szczerbinska A, Cichoz-Lach H Nutrients. 2023; 15(3).

PMID: 36771465 PMC: 9921714. DOI: 10.3390/nu15030760.

Review of pharmacotherapeutic treatments for primary sclerosing cholangitis.

Zhang C, Hussaini T, Yoshida E Can Liver J. 2022; 2(3):58-70.

PMID: 35990218 PMC: 9202752. DOI: 10.3138/canlivj-2018-0016.

PPARα: A potential therapeutic target of cholestasis.

Ye X, Zhang T, Han H Front Pharmacol. 2022; 13:916866.

PMID: 35924060 PMC: 9342652. DOI: 10.3389/fphar.2022.916866.

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Wang C, Shi Y, Wang X, Ma H, Liu Q, Gao Y Front Immunol. 2022; 13:940688.

PMID: 35880178 PMC: 9307989. DOI: 10.3389/fimmu.2022.940688.

References

Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H . A novel treatment for refractory primary biliary cirrhosis?. Hepatogastroenterology. 2001; 47(36):1518-21. View

Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M . The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008; 38(6):557-64. DOI: 10.1111/j.1872-034X.2007.00305.x. View

Lens S, Leoz M, Nazal L, Bruguera M, Pares A . Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2013; 34(2):197-203. DOI: 10.1111/liv.12290. View

Kuiper E, Hansen B, de Vries R, den Ouden-Muller J, van Ditzhuijsen T, Haagsma E . Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009; 136(4):1281-7. DOI: 10.1053/j.gastro.2009.01.003. View

Kumagi T, Guindi M, Fischer S, Arenovich T, Abdalian R, Coltescu C . Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010; 105(10):2186-94. DOI: 10.1038/ajg.2010.216. View

. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014; 44 Suppl S1:71-90. DOI: 10.1111/hepr.12270. View

Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H . Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004; 29(4):216-222. DOI: 10.1016/j.hepres.2004.04.001. View

Willson T, Brown P, Sternbach D, Henke B . The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000; 43(4):527-50. DOI: 10.1021/jm990554g. View

. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014; 44 Suppl S1:1-58. DOI: 10.1111/hepr.12269. View

10.

Marschall H, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J . Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005; 129(2):476-85. DOI: 10.1016/j.gastro.2005.05.009. View

11.

Poupon R . Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010; 52(5):745-58. DOI: 10.1016/j.jhep.2009.11.027. View

12.

Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K . Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000; 95(10):2990-2. DOI: 10.1111/j.1572-0241.2000.03220.x. View

13.

Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H . Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2012; 57(5):1942-9. DOI: 10.1002/hep.26176. View

14.

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

15.

Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M . Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res. 2002; 22(4):250-260. DOI: 10.1016/s1386-6346(01)00148-6. View

16.

Ohmoto K, Yoshioka N, Yamamoto S . Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol. 2006; 41(5):502-3. DOI: 10.1007/s00535-006-1778-1. View

17.

Tanaka A . [Management of PBC cases failing to respond to UDCA]. Nihon Shokakibyo Gakkai Zasshi. 2013; 110(1):16-21. View

18.

Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M . Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000; 95(1):326-7. DOI: 10.1111/j.1572-0241.2000.01667.x. View

19.

Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B . Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009; 44(6):630-4. DOI: 10.1007/s00535-009-0051-9. View

20.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View